Abstract:Proc Amer Assoc Cancer Res, Volume 46, 2005 2589 The PI3K signaling pathway has been known to be up-regulated in many tumors via activation of receptor tyrosine kinases (RTKs) or inactivation of PTEN. It was only realized recently that the PIK3CA gene encoding the catalytic subunit p110α, a member of the PI3K family, is mutated at high frequency in human cancers. Mutations in PIK3CA were found in 40% of breast tumors, making this the most commonly mutated gene in breast cancer. Mutations in PIK3CA cluster into two major “hot spots” located in the helical and kinase domains. To evaluate the oncogenic potential of these mutant forms of p110α and investigate their mechanism(s) of action, we have developed a transformation system utilizing telomerase immortalized primary human mammary epithelial cells (HMECs). The study of kinases in HMECs demanded creation of a system devoid of interfering viral oncogenes. In the absence of viral oncogenes HMECs transformation is dependent on the activation of PI3K for growth in soft agar and as xenografts in mice. Interestingly, the kinase activities and transforming potencies of the two “hot spot” mutant alleles of p110α (E545K and H1047R) derived from human cancers are much higher than those of constitutively activated p110α by myristoylation (Myr-p110α). Unlike activating EGFR mutations, the activation of both E545K and H1047R is independent of growth factor stimulation. Thus HMEC cells transformed with activated PI3K-p110α are relatively insensitive to RTK inhibitors, including specific IGF-1R and EGFR inhibitors. Moreover, tumors derived from transformed HMEC cells expressing constitutively activated PI3K-p110α are highly vascularized particularly in the peripheral zone. We have also constructed a corresponding helical “hot spot” mutant allele in p110α that was roughly 10 fold less effective in activating Akt but still showed residual transforming ability. We have been able to analyze transcriptional profiles of our PI3K transformed HMEC to identify unique signatures of PIK3CA mutants in human breast tumor samples. Finally we have constructed a conditional knockout of the PIK3CA gene in mice to study the role of PI3K-p110α in breast development and breast cancer formation in vivo. Taken together, using our HMEC derived functional transformation system, we have demonstrated the oncogenic potential of tumor derived mutant alleles of PIK3CA in breast cancer formation and established a valuable model for preclinical studies of new specific inhibitors.

The P110 Alpha And P110 Beta Isoforms Of Pi3k Play Divergent Roles In Mammary Gland Development And Tumorigenesis

The role of PI3K-p110α in breast cancer

Biochemical and biological characterization of tumor-associated mutations of p110alpha.

Phosphatidylinositol 3-Kinase: the Oncoprotein.

Class IA PI3K isoforms lead to differential signalling downstream of PKB/Akt

ErbB2-positive Mammary Tumors Can Escape PI3K-p110α Loss Through Downregulation of the Pten Tumor Suppressor

Key role of phosphoinositide 3-kinase class IB in pancreatic cancer

Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Somatic Mutations in P85α Promote Tumorigenesis Through Class IA PI3K Activation

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Helical Domain and Kinase Domain Mutations in P110alpha of Phosphatidylinositol 3-Kinase Induce Gain of Function by Different Mechanisms.

Oncogenic PI3K deregulates transcription and translation

[Clinical Significance of Expression of PI3Kp110α in Breast Cancer].

Advances in Subunits of PI3K Class I in Cancer.

Divergent roles of the regulatory subunits of class IA PI3K

Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models

A Hotspot Variants P.h1047r and P.h1047l in P110α/δnp63α Complex Affects Structure, Function and Contributes to Susceptibility Metastatic Breast Cancer

PI3K Isoforms in CD8+ T Cell Development and Function

PI3Kβ controls immune evasion in PTEN-deficient breast tumours

Theoretical Studies on Beta and Delta Isoform-Specific Binding Mechanisms of Phosphoinositide 3-Kinase Inhibitors.